Efficacy of famotidine in patients with acute gastric mucosal injury after continuous infusion of cisplatin plus vindesine
| Autor: | Kiyoshi Mori, Kohki Yokoyama, Yukari Suga, Izumi Kishiro, Keigo Tominaga, Mitsuji Tsurui |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Randomization Lung Neoplasms Vindesine Duodenum medicine.medical_treatment Placebo Gastroenterology Drug Administration Schedule Bolus (medicine) Double-Blind Method Oral administration Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies Stomach Ulcer Intestinal Mucosa Infusions Intravenous Aged Chemotherapy Gastric Juice business.industry Stomach Hexosamines General Medicine Hydrogen-Ion Concentration Middle Aged Famotidine medicine.anatomical_structure Treatment Outcome Oncology Gastric Mucosa Anesthesia Female Cisplatin business Blood Flow Velocity medicine.drug |
| Zdroj: | Journal of cancer research and clinical oncology. 121(6) |
| ISSN: | 0171-5216 |
| Popis: | The effect of famotidine (H2 blocker) on the gastroduodenal mucosal injury induced by chemotherapy in non-small-cell lung cancer patients was prospectively evaluated from the clinical and endoscopic findings obtained in a randomized double-blind study. The patients, who were administered cisplatin (25 mg/m2/day, continuous infusion, days 1-5) and vindesine (3 mg/m2, bolus, days 1 and 8), were randomized into two groups, those administered famotidine (40 mg/day, oral) and those administered the placebo. The patients were examined by gastroduodenoscopy within 7 days before and after chemotherapy. There were 27 patients in the famotidine group and 28 patients in the placebo group. The gastric mucosal score after chemotherapy was significantly lower in the famotidine group than in the placebo group (P < 0.01), and in the 42 patients without symptoms than in the 13 patients (placebo group: 8, famotidine group: 5) with upper gastrointestinal symptoms (P < 0.01). The pH of the gastric juice after the chemotherapy significantly decreased in the placebo group (P < 0.05), and was significantly lower in the placebo group than in the famotidine group (P = 0.01). The co-administration of famotidine was effective in the prevention and control of chemotherapy-induced gastric mucosal injury. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink